Last reviewed · How we verify
20% human serum albumin
At a glance
| Generic name | 20% human serum albumin |
|---|---|
| Sponsor | Tianjin Huanhu Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Procedural pain
- Arthralgia
- Joint swelling
- Nasopharyngitis
- Muscle spasms
- Anaemia
- Hypotension
- Urinary tract infection
- Joint stiffness
- Headache
- Post procedural contusion
- Dizziness
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Study of DF1001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Recombinant Human Serum Albumin in Healthy Subjects (PHASE1)
- Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects (PHASE1)
- Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites (PHASE2, PHASE3)
- Phase II/III of Recombinant Human Serum Albumin (PHASE2, PHASE3)
- Modulation of Cerebral Ischemia by Albumin (PHASE2)
- Strong Albumin Solutions in Patients With Septic Shock (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 20% human serum albumin CI brief — competitive landscape report
- 20% human serum albumin updates RSS · CI watch RSS
- Tianjin Huanhu Hospital portfolio CI